BRCA2 and neoplasm: RP6685 was another PolD inhibitor reported by Repare, which selectively killed BRCA2 knockout cancer cell line compared to wildtype isogenic.318 RP6685 enhanced micronuclei and DNA damage marker γH2AX in BRCA2 knockout tumor models.